Skip to main content

Table 1 Demographic and clinical data of glioma patients with postoperative recurrence and controls

From: Development of preoperative and postoperative models to predict recurrence in postoperative glioma patients: a longitudinal cohort study

Demographic and Clinical Data

PRa (n = 367)

Controls(n = 2029)

t/Z/χ2

p value

Preoperative Period

 Age at Diagnosis (Years)

54.61 (13.29), 6.00–78.00

43.25 (13.93), 3.00–82.00

t = 14.95

< 0.0001****

 Sex male No. (%)

245 (67)

1152 (57)

χ2 = 12.74

3.59 × 10− 4***

 Illness Duration (Months)

3.97 (15.74), 0.10–240.00

5.73 (14.40), 0.05–240.00

t = -1.96

0.05

 Headache No. (%)

184 (50)

754 (37)

χ2 = 21.96

< 0.0001****

 Dizziness No. (%)

44 (12)

288 (14)

χ2 = 1.27

0.26

 Nausea No. (%)

16 (4)

75 (4)

χ2 = 0.37

0.54

 Vomiting No. (%)

32 (9)

142 (7)

χ2 = 1.37

0.24

 Epilepsy No. (%)

8 (2)

161 (8)

χ2 = 15.70

< 0.0001****

 Intracranial Space-Occupying Lesion or Intracranial Tumora No. (%)

6 (2)

125 (6)

χ2 = 12.32

4.49 × 10− 4***

 Impaired Consciousness No. (%)

41 (11)

416 (21)

χ2 = 17.53

< 0.0001****

 Muscle Twitching No. (%)

39 (11)

439 (22)

χ2 = 23.59

< 0.0001****

 Muscle Weakness No. (%)

84 (23)

232 (11)

χ2 = 35.61

< 0.0001****

 Limb Numbness No. (%)

23 (6)

125 (6)

χ2 = 0.01

0.94

 Speech Disorder No. (%)

46 (13)

145 (7)

χ2 = 12.30

4.54 × 10− 4***

 Memory Deterioration No. (%)

32 (9)

78 (4)

χ2 = 16.86

< 0.0001****

 Slow Reaction No. (%)

22 (6)

31 (2)

χ2 = 28.67

< 0.0001****

 Visual Impairment No. (%)

20 (5)

90 (4)

χ2 = 0.73

0.39

 Lethargy No. (%)

4 (1)

9 (0)

Z = -1.54

0.12

 Family History of Glioma No. (%)

1 (0)

0 (0)

Z = -1.42

0.15

Respiratory Diseases No. (%)

0 (0)

0 (0)

--

--

 Digestive Diseases No. (%)

1 (0)

0 (0)

Z = -1.45

0.15

 Urinary System Diseases No. (%)

0 (0)

2 (0)

Z = 0.00

1.00

 Hematological Disorders No. (%)

0 (0)

0 (0)

--

--

 Endocrine Diseases No. (%)

0 (0)

1 (0)

Z = 0.00

1.00

 Cardiovascular Diseases No. (%)

1 (0)

3 (0)

Z = -0.71

0.47

 Previous Surgical History No. (%)

13 (4)

21 (1)

χ2 = 13.75

2.09 × 10− 4***

 History of Head Trauma No. (%)

0 (0)

6 (0)

Z = -0.53

0.60

Tumor Location

 Frontal lobe No. (%)

155 (42)

1112 (55)

χ2 = 19.71

< 0.0001****

 Parietal lobe No. (%)

55 (15)

274 (14)

χ2 = 0.58

0.45

 Occipital lobe No. (%)

38 (10)

122 (6)

χ2 = 9.40

2.17 × 10− 3**

 Temporal lobe No. (%)

152 (41)

580 (29)

χ2 = 24.12

< 0.0001****

 Insular lobe No. (%)

23 (6)

161 (8)

χ2 = 1.22

0.27

 Corpus Callosum No. (%)

30 (8)

64 (3)

χ2 = 20.78

< 0.0001****

 Thalamus No. (%)

15 (4)

31 (2)

χ2 = 10.81

1.01 × 10− 3**

 Basal ganglia No. (%)

6 (2)

37 (2)

χ2 = 0.06

0.80

 Brainstem No. (%)

0 (0)

10 (0)

Z = -0.88

0.38

 Cerebellum No. (%)

6 (2)

47 (2)

χ2 = 0.67

0.41

 Ventricle No. (%)

12 (3)

61 (3)

χ2 = 0.07

0.79

 Karnofsky Scoreab (%)

80.98 (14.88), 30.00-100.00

84.91 (12.03), 40.00-100.00

t = 4.77

< 0.0001****

Postoperative Period

 WHO Grade 1/2/3/4

1/24/42/300

73/896/403/657

χ2 = 327.14

< 0.0001****

 WHO Grade 1 No. (%)

1 (0)

73 (4)

χ2 = 11.48

7.03 × 10− 4***

 WHO Grade 2 No. (%)

24 (7)

896 (55)

χ2 = 185.95

< 0.0001****

 WHO Grade 3 No. (%)

42 (11)

403 (20)

χ2 = 14.56

1.36 × 10− 4***

 WHO Grade 4 No. (%)

300 (82)

657 (32)

χ2 = 315.70

< 0.0001****

 GFAP + a No. (%)

345 (96)

1948 (97)

χ2  = 1.47

0.23

 OLIG2 + a No. (%)

244 (68)

1593 (80)

χ2 = 25.16

< 0.0001****

 P53 + a No. (%)

197 (55)

923 (47)

χ2 = 9.20

2.43 × 10− 3**

 IDH-1/IDH-2 + a No. (%)

34 (12)

798 (49)

χ2 = 129.91

< 0.0001****

 Ki-67a ≥ 20% No. (%)

99 (28)

294 (15)

χ2 = 36.78

< 0.0001****

 TERT + a No. (%)

79 (54)

483 (54)

χ2 = 0.01

0.91

 1p/19q Codeletiona No. (%)

2 (2)

92 (12)

χ2 = 12.16

4.87 × 10− 4***

 MGMT + a No. (%)

95 (33)

638 (42)

χ2 = 8.27

4.03 × 10− 3**

 EGFR + a No. (%)

28 (93)

84 (73)

χ2 = 5.57

0.02*

 Hospitalization Days

19.58 (10.16), 3.00–99.00

18.05 (8.07), 2.00–131.00

t = -2.70

0.01*

 Chemotherapy/Radiotherapy No. (%)

237 (65)

1674 (83)

χ2 = 61.86

< 0.0001****

 Karnofsky Scoreab (%)

82.35 (18.93), 30.00-100.00

90.63 (12.87), 20.00-100.00

t = 7.52

< 0.0001****

 ECOG Gradea

1.19 (0.91), 0.00–4.00

0.76 (0.70), 0.00–4.00

t = -7.92

< 0.0001****

  1. Continuous data are shown as mean (SD), minimum and maximum values in patients with postoperative recurrence and controls with statistical significance based on two sample t test. Categorical data differences (No. and percentages) in patients with postoperative recurrence and controls are represented with statistical significance based on chi-squared test (χ2 & p) and Fisher exact test (Z & p). *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001
  2. a: The majority of intracranial space-occupying lesion or intracranial tumor were discovered incidentally through accidental injury seeking medical attention or physical examination. PR, postoperative recurrence or death; GFAP+, glial fibrillary acidic protein positive; OLIG2+, oligodendrocyte transcription factor 2 overexpression; P53+, tumor suppressor gene p53 mutation; IDH-1/IDH-2+, isocitrate dehydrogenase 1 or isocitrate dehydrogenase 2 mutation; Ki-67, cell proliferation antigen Ki-67; TERT+, telomerase reverse transcriptase promoter mutation; 1p/19q codeletion, complete deletion of complete deletion of both the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q); MGMT+, O-6-methylguanine-DNA methyltransferase promoter methylation; EGFR+, epidermal growth factor receptor mutation. Karnofsky score refers to an eleven levels rating scale which ranges from normal functioning (100%) to dead (0%) in 10% increments. ECOG Grade refers to a scoring system that measures the extent to which cancer affects a patient’s daily living abilities (performance status) on a scale ranging from 0 (fully active) to 5 (dead).b: 366 patients with PR and 2011 controls attended preoperative KPS score tests, while 319 patients with PR and 1911 controls participated in the postoperative KPS score tests